All In Biotech

Drug Trial Radar · NCT06544291

Combined THC and CBD for OUD and Chronic Pain

Combination of THC and CBD as Novel Treatment for Co-Occurring Opioid Use Disorder and Chronic Pain

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

147

Planned (sponsor's estimate)

Start

Oct 22, 2024

Primary completion

Jan 28, 2028

Study completion Jan 28, 2028

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this phase 2 study is to investigate the therapeutic potential of orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in relieving both pain and cue-induced opioid craving in people with co-occurring opioid use disorder (OUD) and chronic pain who are undergoing methadone therapy.

Conditions

  • Chronic Pain
  • Opioid Use Disorder

Interventions

  • CBD 300mgDrug

    3 Nantheia™ (100mg) softgel capsules and 3 placebo (0mg) softgel capsules will be administered to participants on one of the three test session days.

  • CBD 600mgDrug

    6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.

  • Placebo 0mgDrug

    6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Outcome Variable #1: Pain SensitivityTime frame: Up to 8 hours
  2. Primary Outcome Variable #2: Opioid CravingTime frame: Baseline and +180 minutes post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Connecticut Mental Health Center

    New Haven, Connecticut · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.